Table of Contents
| << Previous Issue | Apr 2012 (Vol: 2012, Issue: 4) | Next Issue >> |
- Section: Features
-
Key Lessons on Royalties Too Often Learned the Hard Way
- Section: Licensing
-
AstraZeneca and Amgen Collaborate to Develop and Commercialise Amgen’s Clinical Inflammation Portfolio
-
Optimer Partners with Astellas Again to Commercialise Fidaxomicin in Japan
-
Merck & Co. Licenses Endocyte’s Phase III Cancer Drug for a Potential US$1 B
- Section: Mergers & Acquisitions
-
Bausch & Lomb Tops Valeant with US$500 M Bid for ISTA
-
Valeant Further Expands in Russia with Natur Produkt Purchase
-
Spectrum Pharmaceuticals Agrees to Acquire Allos Therapeutics After Apaziquone Setback
-
Amgen to Acquire KAI Pharmaceuticals and Gain a Potential Successor to Sensipar®
-
Takeda Looks to Offset Revenue Losses with Bolt-On Acquisition of URL Pharma
-
Shire Strengthens its Regenerative Medicine Business with Pervasis Therapeutics Purchase
-
GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare
-
Piramal Moves Further Away from Branded Generics with Purchase of Bayer Molecular Imaging Assets
-
AstraZeneca Looks to Replenish Late-Stage Pipeline with US$1.26 B Ardea Biosciences Acquisition
PharmaDeals will be moved to a new platform by October 31, 2026. Please look out for an email from your IQVIA account manager by the end of September with details.
RSS